杜皮鲁玛
医学
药物警戒
特应性皮炎
不良事件报告系统
不利影响
贾纳斯激酶
皮肤病科
Janus激酶抑制剂
食品药品监督管理局
安全概况
加药
药品
单纯疱疹病毒
临床试验
鲁索利替尼
单克隆
免疫学
梅德林
过敏
托法替尼
年轻人
内科学
斯科拉德
作者
Yaning Tian,Meixuan Li,Haoyang Hong,Rongfang Feng,Mai Luo,Yumin Xia
摘要
BACKGROUND: Targeted systemic therapies for atopic dermatitis (AD), including biologics and Janus kinase inhibitors, are increasingly used. However, comparative postmarketing evidence on herpetic infection-related safety signals across these therapies remains limited. OBJECTIVES: To compare safety signals of herpetic infections associated with targeted AD therapies using the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: FAERS reports (Q2 2017 to Q1 2025) involving dupilumab, abrocitinib, baricitinib or upadacitinib were included if these agents were designated as the primary suspect drug and the indication was AD. Disproportionality analyses using four algorithms were performed to detect signals for overall and virus-specific herpetic events. Subgroup analyses by age, sex and time to onset (TTO) were conducted. RESULTS: All therapies demonstrated positive signals for herpetic infections. Baricitinib and abrocitinib showed the strongest signals, followed by upadacitinib, whereas dupilumab showed comparatively lower signals overall. Notably, dupilumab demonstrated a herpes simplex virus (HSV) signal comparable with abrocitinib and higher than for upadacitinib, and a signal for eczema herpeticum (EH) was also identified. Signals were generally higher in female patients, except for upadacitinib. Age-stratified analyses showed varying signal patterns across age groups. The median TTO differed between therapies, with an earlier onset for upadacitinib. CONCLUSIONS: Reporting patterns of herpetic infections differ across targeted AD therapies. Disproportionate reporting of HSV and EH with dupilumab warrants further investigation. Differences across sex, age and TTO suggest potential heterogeneity in reporting patterns, which may reflect underlying patient characteristics and reporting behaviours.
科研通智能强力驱动
Strongly Powered by AbleSci AI